Table 1.
Patient baseline characteristics in the two groups
| Sorafenib group (n = 58) | Sorafenib/celecoxib group (n = 58) | P value | |
|---|---|---|---|
| Age | 57.4±11.1 | 51.3±11.7 | 0.004a |
| Gender (M/F) | 52/6 | 56/2 | 0.272b |
| HBsAg | 89.1% | 100.0% | 0.083b |
| ALT | 51.6±68.5 | 72.2±101.4 | 0.229a |
| AST | 53.0±50.2 | 71.0±99.5 | 0.241a |
| TBIL | 14.3±7.1 | 15.1±5.4 | 0.509a |
| ALB | 41.0±4.4 | 41.7±4.9 | 0.551a |
| AFP (< 400/> 400) | 39/16 | 29/17 | 0.401b |
| Child-Pugh (A) | 100.0% | 100.0% | 1.000b |
| Nodules in liver | 0.349b | ||
| None | 17 (29.3%) | 14 (26.4%) | |
| 1 | 14 (24.1%) | 7 (13.2%) | |
| 2 | 2 (3.4%) | 4 (7.5%) | |
| Multiple | 25 (43.1%) | 28 (52.8%) | |
| MVI | 0.038b | ||
| None | 18 (60.0%) | 10 (33.3%) | |
| 1 | 12 (340.0%) | 20 (66.7%) | |
| PVTT | 0.639c | ||
| None | 41 (70.7%) | 33 (62.3%) | |
| 1 | 13 (22.4%) | 15 (28.3%) | |
| 2 | 4 (6.9%) | 5 (9.4%) | |
| HVTT/IVCTT | 0.587c | ||
| None | 51 (87.9%) | 46 (86.8%) | |
| HVTT | 5 (8.6%) | 3 (5.7%) | |
| IVCTT | 2 (3.4%) | 4 (7.5%) | |
| Metastasis | 0.406b | ||
| None | 37 (63.8%) | 33 (61.1%) | |
| Lung | 16 (27.6%) | 12 (22.2%) | |
| Other | 5 (8.6%) | 9 (16.7%) | |
| Previous treatment | 0.108c | ||
| None | 1 (1.7%) | 7 (12.1%) | |
| TACE | 16 (27.6%) | 16 (27.6%) | |
| Surgery | 12 (20.7%) | 13 (22.4%) | |
| TACE + Surgery | 29 (50.0%) | 22 (37.0%) | |
| Length of sorafenib treatment | 427.0 | 263.5 | 0.103d |
Values in bold indicate significance.
a
T-test.
b
χ2 test.
c
Continuity correction.
d
Mann-Whitney U test.
MVI: microvascular invasion; PVTT: portal vein tumor thrombus (1: branch portal vein; 2 trunk portal vein); HVTT: hepatic vein tumor thrombosis; IVCTT: inferior vena cava tumor thrombosis.